---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-017018"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-03-12T23:59:59+00:00"
generated_at: "2026-05-15T13:06:25.881741+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences Q4 net income $20.1M, PBGENE-HBV shows antiviral activity, cash runway through 2028

## Summary
- Q4 net income $20.1M ($1.05 diluted EPS) vs net loss $17.8M YoY; FY net loss $45.7M ($3.56/sh).
- Cash, equivalents, restricted cash $137.2M as of Dec 31, 2025; $75M Nov 2025 financing extends runway through 2028.
- PBGENE-HBV Phase 1: 13 patients dosed across 5 cohorts; late-breaking data showed safety, dose-dependent antiviral activity and HBsAg declines.
- PBGENE-DMD received IND clearance Feb 2026; Fast Track & Orphan Drug designations; initial data from multiple patients expected year-end 2026.
- Milestone payments: $8M from Imugene (Oct 2025) and $7.5M from TG Therapeutics (Mar 2026).

## SEC filing metadata
- accession: 0001628280-26-017018
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/0001628280-26-017018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/dtil-20260312.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-017018
- JSON: https://secwatch.observer/filing/0001628280-26-017018.json
- Plain text: https://secwatch.observer/filing/0001628280-26-017018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.